A 35-year-old man with a history of chronic urticaria and angioedema (not associated with C1-esterase inhibitor deficiency) presents with recurrent episodes triggered by stress and NSAIDs. He has failed to respond to standard H1-antihistamines for 6 weeks. What is the drug of choice for refractory chronic urticaria in this patient?

## Management of Refractory Chronic Urticaria **Key Point:** Omalizumab (anti-IgE monoclonal antibody) is the first-line biologic agent for chronic spontaneous urticaria (CSU) that is unresponsive to standard H1-antihistamines, as per international guidelines (EAACI, GINA, ASCIA). ### Pathophysiology of Chronic Urticaria Chronic urticaria involves: - Mast cell and basophil activation (IgE-dependent or IgE-independent) - Release of histamine, tryptase, and other mediators - Persistent cutaneous and subcutaneous inflammation - Approximately 50% of cases are autoimmune (IgE or IgG against FcεRI or IgE itself) ### Stepwise Treatment Algorithm for Chronic Urticaria ```mermaid flowchart TD A[Chronic Urticaria Diagnosis]:::outcome --> B[First-line: H1-antihistamine]:::action B --> C{Response after 2-4 weeks?}:::decision C -->|Yes| D[Continue antihistamine]:::action C -->|No| E[Escalate: Add omalizumab OR cyclosporine]:::action E --> F{Response after 4-12 weeks?}:::decision F -->|Yes| G[Maintenance therapy]:::action F -->|No| H[Add cyclosporine or consider other biologics]:::action ``` ### Omalizumab: Mechanism and Evidence **Mechanism:** - Binds to circulating IgE and prevents interaction with high-affinity IgE receptor (FcεRI) on mast cells and basophils - Reduces mast cell and basophil activation and degranulation - Effective in both IgE-dependent and IgE-independent (autoimmune) urticaria **Dosing:** - Weight and baseline serum IgE-based dosing (typically 150–375 mg SC every 2–4 weeks) - Onset: 1–4 weeks; maximum benefit at 12 weeks **Evidence:** - Superior efficacy vs. placebo in refractory CSU (ASTERIA-I, ASTERIA-II, GLACIAL trials) - Approved by FDA, EMA, and included in GINA/EAACI guidelines for CSU unresponsive to H1-antihistamines **Clinical Pearl:** Omalizumab is particularly effective in autoimmune urticaria (IgG against FcεRI or IgE). The patient's NSAID-triggered episodes suggest possible underlying mast cell instability, making omalizumab ideal. **High-Yield:** The key phrase in the stem is "failed to respond to standard H1-antihistamines for 6 weeks." This defines refractory CSU and mandates escalation to omalizumab or cyclosporine. ### Comparison of Escalation Options | Agent | Mechanism | Onset | Efficacy | Adverse Effects | Use in CSU | |-------|-----------|-------|----------|-----------------|------------| | **Omalizumab** | Anti-IgE mAb | 1–4 weeks | 60–70% complete response | Rare; anaphylaxis <0.1% | First-line biologic | | **Cyclosporine** | T-cell immunosuppressant | 2–4 weeks | 60–80% response | Nephrotoxicity, HTN, infections | Second-line biologic | | **Prednisolone** (systemic steroid) | Broad immunosuppression | 1–2 weeks | High short-term | Osteoporosis, infections, metabolic | Short-term only; not maintenance | | **H1-antihistamines** (standard dose) | H1-receptor antagonism | 1–2 hours | 30–50% in CSU | Sedation (first-gen) | First-line; inadequate here | ### Why Prednisolone Is Not First-Line Escalation - Systemic corticosteroids are reserved for acute exacerbations or as a bridge therapy - Long-term use carries unacceptable risk of osteoporosis, infection, and metabolic complications - Guidelines recommend biologics (omalizumab, cyclosporine) before systemic steroids for maintenance **Warning:** A common exam trap is selecting "higher-dose H1-antihistamine" or "systemic corticosteroid" for refractory CSU. Both are incorrect escalation strategies per GINA/EAACI guidelines.